Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label, Randomized, Controlled Trial of DN022150 Monotherapy Versus Investigator's Choice Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

NCT07689539 is registered in ClinicalTrials.gov with Jiangxi Kvvit Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07689539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07689539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label, Randomized, Controlled Trial of DN022150 Monotherapy Versus Investigator's Choice Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
Lead sponsor
Jiangxi Kvvit Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2028
Enrollment
360 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer